Results 91 to 100 of about 53,280 (246)

Long‐term outcomes of children with ulcerative colitis after acute severe colitis: A GETAID pédiatrique multicenter study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Acute severe colitis (ASC) is a frequent and severe complication of ulcerative colitis (UC) with a high risk of colectomy. Effects of immunosuppressants and anti–tumor necrosis factor (anti‐TNF) agents on the risk of colectomy remain debated. We wished to study the evolution of French pediatric‐onset UC patients after ASC.
Manon Cochet, Agathe Beauvais, Frank Ruemmele, Raphael Enaud, Thierry Lamireau, Rémi Duclaux‐Loras, Claire Dupont, Stéphanie Willot, Laure Bridoux‐Henno, Georges Dimitrov, Julie Lemale, Vincent Guinard‐Samuel, Valérie Bertrand, Anne Breton, Christine Martinez Vinson, Stéphanie Coopman, Delphine Ley, Bénédicte Pigneur, and the Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du tube Digestif (GETAID) pédiatrique   +18 more
wiley   +1 more source

Successful treatment of eosinophilic esophagitis with upadacitinib prescribed for atopic dermatitis

JPGN Reports, EarlyView.
Abstract We describe a pediatric patient treated with upadacitinib for atopic dermatitis (AD) who subsequently achieved sustained clinical and histologic remission of eosinophilic esophagitis (EoE). Upadacitinib is an oral small molecule selective Janus kinase 1 inhibitor that inhibits janus kinase‐signal transduction and activation of transcription ...
Nathalie Nguyen, Maureen Bauer
wiley   +1 more source

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan, Christian Wysocki, Bhaskar Gurram   +2 more
wiley   +1 more source

Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques [PDF]

, 2016
Objectives To explore the effects of tofacitinib—an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA)—with or without methotrexate (MTX), on MRI endpoints in MTX-naive adult patients with early active RA and synovitis in an index
American College of Rheumatology Rheumatoid Arthritis Clinical Trials Task Force Imaging Group and Outcome Measures in Rheumatology Magnetic Resonance Imaging Inflammatory Arthritis Working Group, Axelsen, Axelsen, Axelsen, Axelsen, Baker, Bethanie Wilkinson, Bombardier, Bowes, Bowes, Bradley T Wyman, Bruynesteyn, Burmester, Chunying Wu, Conaghan, Conaghan, Cootes, Durez, Désirée van der Heijde, Døhn, Ejbjerg, Fedra Irazoque-Palazuelos, Fleischmann, Fleischmann, Haavardsholm, Haavardsholm, Haavardsholm, Hetland, John D Bradley, Koshika Soma, Kosta, Kremer, Kremer, Kremer, Kubassova, Lee, Michael A Bowes, Mikkel Østergaard, Oscar Soto-Raices, Pawel Hrycaj, Peterfy, Peterfy, Philip G Conaghan, Quinn, Richard Zhang, Strand, Tanaka, Tanaka, Thomas Fuerst, van der Heijde, van der Heijde, van Vollenhoven, Wollenhaupt, Zhiyong Xie, Østergaard   +54 more
core   +1 more source

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos, Line Kibsgaard, Trine Bertelsen   +2 more
wiley   +1 more source

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

Arthritis Research & Therapy
Background Data on treatment switching directly from tumor necrosis factor inhibitors to tofacitinib in psoriatic arthritis (PsA) are limited. This post hoc analysis assessed efficacy and safety outcomes in patients with PsA who directly switched to ...
Dafna D. Gladman, Peter Nash, Philip J. Mease, Oliver FitzGerald, Stephanie Duench, Mary Jane Cadatal, Karim R. Masri   +6 more
doaj   +1 more source

Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside—a Comprehensive Review [PDF]

, 2016
Throughout life, bone is continuously remodelled. Bone is formed by osteoblasts, from mesenchymal origin, while osteoclasts induce bone resorption. This process is tightly regulated. During inflammation, several growth factors and cytokines are increased
Alves, C.H. (Celso Henrique), Colin, E.M. (Edgar), Farrell, E. (Eric), Lubberts, E.W. (Erik), Vis, M. (Marijn)   +4 more
core   +1 more source

HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal, Emily Moon, Georgios Kallikas   +2 more
wiley   +1 more source

Emerging Therapies for the Treatment of Psoriasis [PDF]

, 2012
Psoriasis is an immune-mediated disease that affects 1%–2% of the European and North American population. While topical agents such as corticosteroids and vitamin D derivatives are prescribed for mild disease, they are generally unable to adequately ...
Alan Menter, Antoinette Day, Mahir Patel, Richard B. Warren   +3 more
core   +1 more source

Recalcitrant Eyelid Lupus Treated With Topical Ruxolitinib

JEADV Clinical Practice, EarlyView.
ABSTRACT Lupus of the eyelids, or lupus blepharitis, is a rare and localized form of chronic cutaneous lupus. The use of topical corticosteroids is limited in this sensitive area due to the risk of adverse events. We present a case of eyelid lupus, with histological confirmation, resistant to multiple lines of treatment, successfully treated with ...
Clémence Bertold, Feriel Boukari, Valérie Elmaleh, Julia Bonnelye, Ulysse Jacquier, Nathalie Cardot‐Leccia, Thierry Passeron   +6 more
wiley   +1 more source